FGF Homologs

Details FGF Homologs FGF Homologs

1999-08-05

2002-03-05

Mertz, Prema (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C435S007100, C530S350000, C530S387100, C424S192100

Reexamination Certificate

active

06352971

ABSTRACT:

BACKGROUND OF THE INVENTION
The fibroblast growth factor (FGF) family consists of at least nine distinct members (Basilico et al.,
Adv. Cancer Res.
59:115-165, 1992 and Fernig et al.,
Prog. Growth Factor Res.
5(4):353-377, 1994) which generally act as mitogens for a broad spectrum of cell types. For example, basic FGF (also known as FGF-2) is mitogenic in vitro for endothelial cells, vascular smooth muscle cells, fibroblasts, and generally for cells of mesoderm or neuroectoderm origin, including cardiac and skeletal myocytes (Gospodarowicz et al.,
J. Cell. Biol.
70:395-405, 1976; Gospodarowicz et al.,
J. Cell. Biol.
89:568-578, 1981 and Kardami,
J. Mol. Cell. Biochem.
92:124-134, 1990). In vivo, bFGF has been shown to play a role in avian cardiac development (Sugi et al.,
Dev. Biol.
168:567-574, 1995 and Mima et al.,
Proc. Nat'l. Acad. Sci.
92:467-471, 1995), and to induce coronary collateral development in dogs (Lazarous et al.,
Circulation
94:1074-1082, 1996). In addition, non-mitogenic activities have been demonstrated for various members of the FGF family. Non-proliferative activities associated with acidic and/or basic FGF include: increased endothelial release of tissue plasminogen activator, stimulation of extracellular matrix synthesis, chemotaxis for endothelial cells, induced expression of fetal contractile genes in cardiomyocytes (Parker et al.,
J. Clin. Invest.
85:507-514, 1990), and enhanced pituitary hormonal responsiveness (Baird et al.,
J. Cellular Physiol.
5:101-106, 1987.)
Several members of the FGF family do not have a signal sequence (aFGF, bFGF and possibly FGF-9) and thus would not be expected to be secreted. In addition, several of the FGF family members have the ability to migrate to the cell nucleus (Friesel et al.,
FASEB
9:919-925, 1995). All the members of the FGF family bind heparin based on structural similarities. Structural homology crosses species, suggesting a conservation of their structure/function relationship (Ornitz et al.,
J. Biol. Chem.
271(25):15292-15297, 1996.)
There are four known extracellular FGF receptors (FGFRs), and they are all tyrosine kinases. In general, the FGF family members bind to all of the known FGFRs, however, specific FGFs bind to specific receptors with higher degrees of affinity. Another means for specificity within the FGF family is the spatial and temporal expression of the ligands and their receptors during embryogenesis. Evidence suggests that the FGFs most likely act only in autocrine and/or paracrine manner, due to their heparin binding affinity, which limits their diffusion from the site of release (Flaumenhaft et al.,
J. Cell. Biol.
111(4):1651-1659, 1990.) Basic FGF lacks a signal sequence, and is therefore restricted to paracrine or autocrine modes of action. It has been postulated that basic FGF is stored intracellularly and released upon tissue damage. Basic FGF has been shown to have two receptor binding regions that are distinct from the heparin binding site (Abraham et al.,.
EMBO J.
5(10):2523-2528, 1986.)
It has been shown that FGFR-3 plays a role in bone growth. Mice made homozygous null for the FGFR-3 (−/−) resulted in postnatal skeletal abnormalities (Colvin et al.,
Nature Genet.
12:309-397, 1996 and Deng et al.,
Cell
84:911-921, 1996) The mutant phenotype suggests that in normal mice, FGFR-3 plays a role in regulation of chrondrocyte cell division in the growth plate region of the bone (Goldfarb,
Cytokine and Growth Factor Rev.
7(4):311-325, 1996). The ligand for the FGFR-3 in the bone growth plate has not been identified.
Although four FGFRs have been identified, all of which have been shown to have functional splice variants, the possibility that novel FGF receptors exist is quite likely. For example, no receptor has been identified for the FGF-8a isoform (MacArthur et al.,
J. Virol.
69(4):2501-2507, 1995.).
FGF-8 is a member of the FGF family that was originally isolated from mammary carcinoma cells as an androgen-inducible mitogen. It has been mapped to human chromosome 10q25-q26 (White et al.,
Genomics
30:109-11, 1995.) FGF-8 is involved in embryonic limb development (Vogel et al.,
Development
122:1737-1750, 1996 and Tanaka et al.,
Current Biology
5(6):594-597, 1995.) Expression of FGF-8 during embryogenesis in cardiac, urogenital and neural tissue indicates that it may play a role in development of these tissues (Crossley et al.,
Development
121:439-451, 1995.) There is some evidence that acrocephalosyndactylia, a congenital condition marked by peaked head and webbed fingers and toes, is associated with FGF-8 point mutations (White et al., 1995, ibid.)
FGF-8 has five exons, in contrast to the other known FGFs, which have only three exons. The first three exons of FGF-8 correspond to the first exon of the other FGFs (MacArthur et al.,
Development
121:3603-3613, 1995.) The human gene for FGF-8 codes for four isoforms which differ in their N-terminal regions: FGF isoforms a, b, e, and f; in contrast to the murine gene which gives rise to eight FGF-8 isoforms (Crossley et al., 1995, ibid.) Human FGF-8a and FGF-8b have 100% homology to the murine proteins, and FGF-8e and FGF-8f proteins are 98% homologous between human and mouse (Gemel et al.,
Genomics
35:253-257, 1996.)
Heart disease is the major cause of death in the United States, accounting for up to 30% of all deaths. Myocardial infarction (MI) accounts for 750,000 hospital admissions per year in the U.S., with more than 5 million people diagnosed with coronary disease. Risk factors for MI include diabetes mellitus, hypertension, truncal obesity, smoking, high levels of low density lipoprotein in the plasma or genetic predisposition.
Cardiac hyperplasia is an increase in cardiac myocyte proliferation, and has been demonstrated to occur with normal aging in the human and rat (Olivetti et al.,
J. Am. Coll. Cardiol.
24(1):140-9, 1994 and Anversa et al.,
Circ. Res.
67:871-885, 1990), and in catecholamine-induced cardiomyopathy in rats (Deisher et al.,
Am. J. Cardiovasc. Pathol.
5(1):79-88, 1994.) Whether the increase in myocytes originate with some progenitor, or are a result of proliferation of a more terminally differentiated cell type, remains controversial.
However, because infarction and other causes of myocardial necrosis appear to be irreparable, it appears that the normal mechanisms of cardiac hyperplasia cannot compensate for extensive myocyte death and there remains a need for exogenous factors that promote hyperplasia and ultimately result in renewal of the heart's ability to function.
Bone remodeling is the dynamic process by which tissue mass and skeletal architecture are maintained. The process is a balance between bone resorption and bone formation, with two cell types thought to be the major players. These cells are the osteoblast and osteoclast. Osteoblasts synthesize and deposit matrix to become new bone. The activities of osteoblasts and osteoclasts are regulated by many factors, systemic and local, including growth factors.
While the interaction between local and systemic factors has not been completely elucidated, there does appear to be consensus that growth factors play a key role in the regulation of both normal skeletal remodeling and fracture repair. Some of the growth factors that have been identified in bone include: IGF-I, IGF-II, TGF-&bgr;
1
, TGF-&bgr;
2
, bFGF, aFGF, PDGF and the family of bone morphogenic proteins (Baylink et al.,
J. Bone Mineral Res.
8 (Supp. 2):S565-S572, 1993).
When bone resorption exceeds bone formation, a net loss in bone results, and the propensity for fractures is increased. Decreased bone formation is associated with aging and certain pathological states. In the U.S. alone, there are approximately 1.5 million fractures annually that are attributed to osteoporosis. The impact of these fractures on the quality of the patient's life is immense. Associated costs to the health care system in the U.S. are estimated to be $5-$10 billion annually, excluding long-term care costs.
Other therapeutic applications fo

Affiliated with

Also associated with

Rating

FGF Homologs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with FGF Homologs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and FGF Homologs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2846184